We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avastin Decision Reveals Broader Issues with Trials, Drug Approvals
Avastin Decision Reveals Broader Issues with Trials, Drug Approvals
July 20, 2011
An FDA advisory panel’s recent recommendation to nix the metastatic breast cancer (MBC) indication for Genentech’s Avastin is likely to change the way drug sponsors develop cancer trial endpoints and the way the FDA regulates the accelerated approval process.